Growth of a fifth for Sandoz’ Biopharmaceuticals business – driven by the continued success of its biosimilars portfolio, in Europe and elsewhere – has offset the negative impact of COVID-19 on the company’s retail generics business in 2020, allowing the Novartis off-patent unit to report sales that were steady compared to the previous year.
The company’s $9.646bn turnover total represented a 1% decline as reported, but was flat at constant currencies, with overall volume...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?